JP2005535675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005535675A5 JP2005535675A5 JP2004522385A JP2004522385A JP2005535675A5 JP 2005535675 A5 JP2005535675 A5 JP 2005535675A5 JP 2004522385 A JP2004522385 A JP 2004522385A JP 2004522385 A JP2004522385 A JP 2004522385A JP 2005535675 A5 JP2005535675 A5 JP 2005535675A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- thyroid carcinoma
- ret kinase
- methylpiperazin
- ylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 claims description 8
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 201000002980 Hyperparathyroidism Diseases 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 206010010539 Congenital megacolon Diseases 0.000 claims description 2
- 206010011659 Cutaneous amyloidosis Diseases 0.000 claims description 2
- 208000004592 Hirschsprung disease Diseases 0.000 claims description 2
- 208000005890 Neuroma Diseases 0.000 claims description 2
- 208000015413 lichen amyloidosis Diseases 0.000 claims description 2
- 208000025061 parathyroid hyperplasia Diseases 0.000 claims description 2
- 208000028591 pheochromocytoma Diseases 0.000 claims description 2
- -1 4-Methylpiperazin-1-ylmethyl Chemical group 0.000 claims 2
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 2
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 claims 2
- 201000011523 endocrine gland cancer Diseases 0.000 claims 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 2
- 208000006274 Brain Stem Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000006508 oncogene activation Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39840902P | 2002-07-24 | 2002-07-24 | |
| PCT/IB2003/001984 WO2004009087A1 (en) | 2002-07-24 | 2003-05-23 | 4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005535675A JP2005535675A (ja) | 2005-11-24 |
| JP2005535675A5 true JP2005535675A5 (enExample) | 2006-07-06 |
Family
ID=30771216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004522385A Pending JP2005535675A (ja) | 2002-07-24 | 2003-05-23 | 変異型ｒｅｔキナーゼ関連疾患を処置するための４−（４−メチルピペラジン−１−イルメチル）−ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イルアミノ］フェニル］−ベンズアミド |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20060116381A1 (enExample) |
| EP (1) | EP1526854A1 (enExample) |
| JP (1) | JP2005535675A (enExample) |
| CN (1) | CN1668306A (enExample) |
| AU (1) | AU2003232960A1 (enExample) |
| BR (1) | BR0312873A (enExample) |
| CA (1) | CA2493000A1 (enExample) |
| WO (1) | WO2004009087A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1899616A (zh) * | 2006-07-20 | 2007-01-24 | 中国人民解放军军事医学科学院生物工程研究所 | 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途 |
| BR122019024201B1 (pt) | 2010-05-20 | 2021-08-03 | Array Biopharma Inc | Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| CA2992586A1 (en) | 2015-07-16 | 2017-01-19 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| RS65069B1 (sr) * | 2015-11-02 | 2024-02-29 | Blueprint Medicines Corp | Inhibitori ret-a |
| AR107912A1 (es) | 2016-03-17 | 2018-06-28 | Blueprint Medicines Corp | Inhibidores de ret |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| TWI752098B (zh) | 2016-10-10 | 2022-01-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JP6888101B2 (ja) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
| EP3740486A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| SG11202009681YA (en) | 2018-04-03 | 2020-10-29 | Blueprint Medicines Corp | Ret inhibitor for use in treating cancer having a ret alteration |
| ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
| CN112574201B (zh) * | 2019-09-29 | 2024-04-19 | 四川科伦博泰生物医药股份有限公司 | 芳基胺类化合物、包含其的药物组合物及其制备方法和用途 |
| WO2021243192A1 (en) | 2020-05-29 | 2021-12-02 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| CR20220666A (es) | 2020-05-29 | 2023-05-05 | Blueprint Medicines Corp | Composiciones farmacéuticas de pralsetinib |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5543520A (en) * | 1993-10-01 | 1996-08-06 | Ciba-Geigy Corporation | Pyrimidine derivatives |
| CO4940418A1 (es) * | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
-
2003
- 2003-05-23 WO PCT/IB2003/001984 patent/WO2004009087A1/en not_active Ceased
- 2003-05-23 JP JP2004522385A patent/JP2005535675A/ja active Pending
- 2003-05-23 BR BR0312873-3A patent/BR0312873A/pt not_active IP Right Cessation
- 2003-05-23 EP EP03727759A patent/EP1526854A1/en not_active Withdrawn
- 2003-05-23 CN CNA038173344A patent/CN1668306A/zh active Pending
- 2003-05-23 CA CA002493000A patent/CA2493000A1/en not_active Abandoned
- 2003-05-23 AU AU2003232960A patent/AU2003232960A1/en not_active Abandoned
- 2003-05-23 US US10/521,927 patent/US20060116381A1/en not_active Abandoned
-
2007
- 2007-07-26 US US11/828,374 patent/US20070265274A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005502635A5 (enExample) | ||
| BR0312873A (pt) | 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante | |
| JP2023506532A5 (enExample) | ||
| PL362148A1 (en) | Treatment of gastrointestinal stromal tumors | |
| MY129772A (en) | Crystal modification of a n-phenyl- 2 - pyrimidineamine derivative, processes for its manufacture and its use | |
| JP2006514689A5 (ja) | １−オキソ−２−（２，６−ジオキソピペリジン−３−イル）−４−メチルイソインドリンを含む脳腫瘍の治療及び管理のための医薬組成物 | |
| JP2003520195A5 (enExample) | ||
| JP2009536161A5 (enExample) | ||
| JP2003528095A5 (enExample) | ||
| RU98114837A (ru) | Применение замещенных имидазолидин-2,4-дионовых соединений в качестве обезболивающих средств | |
| RU2005117374A (ru) | Индолы, полезные для лечения заболеваний, связанных с андрогеновыми рецепторами | |
| CY1108061T1 (el) | Παραγωγα κιναζολινης ως src αναστολεις κινασης τυροσινης | |
| CA2492138A1 (en) | N-phenyl-(2r,5s)dimethylpiperazine derivative | |
| JP2008513510A5 (enExample) | ||
| JP2005521650A5 (enExample) | ||
| CA2526989A1 (en) | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | |
| Mallick et al. | Giant cell-rich osteosarcoma–A rare case | |
| JP2009532438A5 (enExample) | ||
| JP2004524279A5 (enExample) | ||
| Pericot et al. | Survival evaluation of treatment modality in squamous cell carcinoma of the oral cavity and oropharynx | |
| JP2007515467A5 (enExample) | ||
| JP2020534266A5 (enExample) | ||
| JP2005538974A5 (enExample) | ||
| JP2011524362A5 (enExample) | ||
| Cho et al. | SBF1:: BRAF-Fused Melanoma With Prominent Rhabdoid Morphology and Reed–Sternberg-Like Cells: Potential Morphologic Clues to BRAF-Fused Melanomas of Non-Spitz Lineage? |